What does long-term success after bariatric surgery look like four years later, especially when GLP-1 medications, strength training, nutrition, and maintenance all become part of the journey?

In this episode, Zoe and Dr. Matthew Weiner are joined by Graham Hoffman, a Pound of Cure patient and peer leader, to talk about life four years after weight loss surgery. Graham shares how GLP-1 medications, strength training, walking, protein-forward nutrition, and long-term support helped him move beyond the number on the scale and build a healthier, more sustainable lifestyle.

They discuss why strength training can be more approachable than endless cardio, how building muscle supports metabolism after bariatric surgery, and why success is not just about reaching a goal weight. Graham also explains how GLP-1s helped reduce food noise, support maintenance, and make it easier to listen to hunger and fullness cues.

They also talk about real-life nutrition strategies after weight loss surgery, including protein coffee, blueberries for fiber, prepared meals, protein-forward snacks, roasted vegetables, planned indulgences, and learning how to leave food on the plate without guilt or shame.

Most importantly, Graham explains why long-term weight loss maintenance is not about being perfect. Sustainable success comes from consistency, support, strength, flexibility, and building habits that can actually last.

Can Medicare patients get GLP-1 medications like Wegovy and Zepbound for $50 per month through the new Medicare GLP-1 Bridge Program?

In this episode, Zoe is joined by Dr. Matthew Weiner and Deidre, FNP, to break down what Medicare patients need to know about the CMS Medicare GLP-1 Bridge Program. They explain who may qualify, why Medicare Part D coverage matters, and why the process is more complicated than simply getting a prescription.

Deidre walks through the eligibility requirements, including BMI, prediabetes, cardiovascular disease, uncontrolled hypertension, sleep apnea, diabetes, and fatty liver disease. She also explains why some patients may not be able to use the Bridge Program if their GLP-1 medication can already be covered through their regular Medicare Part D benefits.

They also discuss the two-step prior authorization process, the $50 monthly copay, why that copay may not count toward a deductible, and why documentation for a structured nutrition and lifestyle program is required.

Most importantly, the team explains what patients should realistically expect as the program rolls out, why delays and confusion are likely at first, and how Pound of Cure is preparing to help eligible Arizona patients navigate access to GLP-1 medications.

What is GLP-1 microdosing, and can smaller doses of medications like Ozempic, Wegovy, and Zepbound lead to better long-term weight loss results?

In this episode, registered dietitian Zoe is joined by Deidre, FNP, to break down one of the biggest conversations in obesity medicine right now: GLP-1 microdosing. They explain how microdosing differs from standard manufacturer dosing, why FDA-approved dosing schedules are designed for clinical trials, and why a one-size-fits-all approach may not work for every patient.

Deidre explains how slower, smaller dose increases may help reduce side effects like nausea and abdominal discomfort, while still supporting hunger control, fewer cravings, less food noise, and gradual weight loss. They also discuss super responders, non-responders, compounded medications, and why personalized GLP-1 dosing can make a major difference in long-term maintenance.

They also unpack the debate around GLP-1 microdose marketing, including the recent dispute involving Eli Lilly, Noom, and tirzepatide, and what it means for patients navigating telehealth weight loss programs.

Most importantly, Zoe and Deidre explain why medications are only one part of obesity treatment. Sustainable weight loss still depends on nutrition, whole foods, protein, fiber, lifestyle changes, and long-term support.